[Immunomodulating effect of thymus protein fraction on disorders of general immunity in patients with lung carcinoma].
The parameters of both cellular and humoral non-specific immunity were evaluated in non-small lung cancer patients (n = 26) prior to therapy, in 13 of them after radiotherapy (45 Gy in 22 fractions) and in 13 patients after combined radio-and immunotherapy (Thymex L, 1800 mg in 12 injections á 150 mg i.m., three times a week). Several parameters of general immunocompetence were altered in patients even before any therapy. The radiotherapy caused more severe immunologic disturbances, the cellular immunity being affected more profoundly. Thymex L., when given simultaneously with radiotherapy, prevented this deterioration in a majority of patients.
Vucković-Dekić
Lj
Lj
Institute of Oncology and Radiology, Beograd.
Susnjar
S
S
Stanojević-Bakić
N
N
Rajner
L
L
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000532:radiotherapy / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008175:Lung Neoplasms / Q000276:immunology* / Q000532:radiotherapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis; D013949:Thymus Extracts / Q000627:therapeutic use*
D013949:Thymus Extracts; C092820:Thymex-L
Imunomodulatorna dejstva proteinske frakcije timusa na poremećaj opste imunosti u bolesnika sa karcinomom pluća.